BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Grant

Date/time Interval

  • April 21, 2017 - April 20, 2019
  • Total Award Amount

  • 28636.00
  • Direct Costs

  • 19284.00
  • Sponsor Award Id

  • 10022
  • Contributor

  • Antonio Di Stasi M.D.   Investigator  
  • Donna Salzman M.D.   Investigator  
  • Kelly Godby M.D.   Investigator  
  • Lorena De Idiaquez Bakula   Investigator  
  • Luciano Costa M.D., Ph.D.   Investigator  
  • Racquel Innis-Shelton M.D.   Principal Investigator  
  • Ravi Bhatia M.D.   Investigator